Clinical Trials

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06832982 2026-04-09

Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002

Phase 1 Recruiting

66 enrolled

Advanced Solid Tumors

NCT06457503 2026-04-06

TRANSPARENT

Phase 4 Recruiting

100 enrolled

Head & Neck

Nasopharyngeal Neoplasms

NCT06657144 2026-04-06

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Phase 1 Recruiting

154 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06975293 2026-04-06

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

Phase 1/2 Not yet recruiting

107 enrolled

Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT07508761 2026-04-02

IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors

52 enrolled

Advanced Solid Tumor

NCT06953323 2026-03-27

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

86 enrolled

Advanced Solid Tumor

NCT07481058 2026-03-20

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

60 enrolled

Phase 2 Enrolling by invitation

Esophageal Squamous Cell Carcinoma

NCT05635643 2026-03-19

Study of CHS-114 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

87 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT05441475 2026-02-25

A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients

118 enrolled

Carcinoma, Hepatocellular

NCT07281976 2026-02-12

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

220 enrolled

Phase 3 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07392060 2026-02-06

A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment

440 enrolled

Gynecologic

Cervical Cancer Metastatic

NCT07392736 2026-02-06

A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.

228 enrolled

Phase 1/2 Active not recruiting

Solid Tumor

NCT05518045 2026-02-04

A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors

392 enrolled

Phase 1/2 Active not recruiting

Advanced Solid Tumor

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

500 enrolled

Solid Cancer

NCT06984588 2026-01-30

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

Phase 2/3 Active not recruiting

450 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07362186 2026-01-23

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Phase 3 Not yet recruiting

400 enrolled

Locally Advanced or Metastatic GC and GCJ Adenocarcinoma

NCT04284488 2026-01-08

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

Phase 1/2 Terminated

Advanced Solid Tumor

NCT07314723 2026-01-02

9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer

90 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT07111832 2025-12-18

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Phase 3 Recruiting

400 enrolled

Triple Negative Breast Neoplasms

NCT07258979 2025-12-02

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

GastrointestinalGenitourinaryThoracic

202 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT04374877 2025-11-10

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Phase 1 Completed

145 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Neoplasms

NCT05386888 2025-10-02

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

Phase 2 Completed

65 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06178159 2025-10-01

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT05980481 2025-09-29

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

201 enrolled

Stomach Neoplasms

NCT06623136 2025-09-26

A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06682780 2025-09-25

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

320 enrolled

Advanced Solid Tumor

NCT05934331 2025-09-12

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

276 enrolled

Other neoplasm

Malignant Neoplasms of Digestive Organs

NCT06868199 2025-09-12

A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

87 enrolled

Advanced Solid Tumours

NCT07169994 2025-09-12

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

414 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06088004 2025-08-22

Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors

218 enrolled

Solid Tumor, Adult

NCT06208410 2025-07-25

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

306 enrolled

Advanced Solid Tumors

NCT04991506 2025-06-23

A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

Phase 1 Completed

30 enrolled

Tumor-Agnostic

Neoplasms

NCT05102006 2025-06-03

A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors

Phase 1/2 Active not recruiting

80 enrolled

Advanced Malignant Tumors

NCT04322006 2025-05-22

A Phase I/II Study of TJ004309 for Advanced Solid Tumor

376 enrolled

Advanced Solid Tumor

NCT04914286 2025-05-14

A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors

148 enrolled

Advanced Solid Tumor

NCT05830539 2025-05-02

IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

68 enrolled

Phase 1 Active not recruiting

Locally Advanced or Metastatic Solid Tumors

NCT05757492 2025-05-01

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Phase 1 Terminated

22 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular

NCT05167071 2025-04-27

HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study

53 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT06823427 2025-03-21

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Phase 2 Not yet recruiting

60 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06873854 2025-03-13

A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours

84 enrolled

Advanced Solid Tumor

NCT04785196 2025-02-26

APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

95 enrolled

Sarcoma

Liposarcoma

NCT05188664 2025-02-17

Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

20 enrolled

Advanced Solid Tumor

NCT06642545 2025-02-17

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

Breast Neoplasms

NCT06038396 2025-01-29

A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors

48 enrolled

Advanced Solid Tumor

NCT05031494 2025-01-06

A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers

Phase 2 Completed

Dermatologic

Melanoma

NCT05615974 2024-12-19

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

139 enrolled

Tumor-Agnostic

Neoplasms

NCT06117566 2024-11-25

A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors

100 enrolled

GastrointestinalHead & NeckSarcoma

Solid Tumor

NCT03474640 2024-11-22

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

Phase 1 Completed

184 enrolled 20 charts

Nasopharyngeal Carcinoma, Chondrosarcoma, Esophageal Neoplasms, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms

NCT06410703 2024-10-31

CAN1012 Combined With PD-1 in Patients With Solid Tumors

71 enrolled